Clinical Trials | April 22, 2026
Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Targets high-growth eye care expansion push
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Policy symposium in Hyderabad focuses on life skills education and community?driven solutions
The new facility is expected to significantly improve access to high-quality medical services for patients across Gujarat and neighbouring regions
The programme has already drawn over 120 complex percutaneous coronary intervention (PCI) case submissions from across the country
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Subscribe To Our Newsletter & Stay Updated
